In the first half of 2022, Qiming Medical returned to mother to a net loss of 200 million yuan, and the loss expanded by 76.83% year -on -year

On August 31, 2022, the Hong Kong stock listed company Qiming Medical-B (code: 02500.HK) released the 2022 fiscal year.

From January 1, 2022 to June 30, 2022, the company's operating income was 210 million yuan, a year-on-year decrease of 12.25%, and the net loss of the parent company was 200 billion yuan, the loss expanded by 76.83%year-on-year, and the basic earnings per share were -0.46 yuan.

The company's industries are health care equipment.

During the company's reporting period, the total assets at the end of the period were 6.333 billion yuan, and the profit before tax was -246 million yuan.

Hangzhou Qiming Medical Device Co., Ltd. was established on July 3, 2009.According to the 2018 implantation meter, the company is China's leading pipe tube cardiac valve medical device company.According to the information of Fhstana, according to 2018 TAVR product implantation meter, the company's market share in China was 79.3%.The company's independent product Venusa-Valve is the first TAVR product approved by NMPA and commercialized in China.

- END -